Today, angiogenesis is the central focus in the pathogenesis of this disease, with VEGF identified as a major mediator of this process. These advances have opened the door for targeted anti-VEGF ...

The drug also showed potential efficacy in patients who failed to optimally respond to anti-VEGF treatment. Results of a phase IIb trial comparing UBX1325 to anti-VEGF therapy are expected later ...

The retrospective analysis included 167 patients with a suboptimal response to anti-VEGF treatment. “We either continued them on standard-of-care anti-VEGF injections or DEX implant was initiate ...